Ligand PharmaceuticalsFRA:LGDN +1.53%73 Days Inventory is 285.35 as of Mar. 2026, which is 28% above its 10-year median of 223.03. GuruFocus rates FRA:LGDN with a GF Score™ of 73/100 and a GF Value™ of €150.40 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 638 Biotechnology companies, Ligand Pharmaceuticals ranks worse than 68.97% on this metric.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Ligand Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.32.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ligand Pharmaceuticals's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.20.
Ligand Pharmaceuticals (FRA:LGDN) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Ligand Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ligand Pharmaceuticals's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Ligand Pharmaceuticals Days Inventory Related Terms
Ligand Pharmaceuticals Days Inventory Historical Data
* Premium members only.
The historical data trend for Ligand Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LGDN vs DFTX, CGON, XENE: Days Inventory Comparison
For the Biotechnology subindustry, Ligand Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ligand Pharmaceuticals Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Ligand Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ligand Pharmaceuticals (FRA:LGDN) has a Days Inventory of 285.35 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Ligand Pharmaceuticals and its competitors. This is 28% above median its historical median of 223.03. Over the past decade, Ligand Pharmaceuticals' Days Inventory has ranged from 116.49 to 646.93. According to the industry distribution chart, Ligand Pharmaceuticals ranks #440 out of 638 companies in the Biotechnology industry, placing it in the top 69%.
Is Ligand Pharmaceuticals' Days Inventory too high?
Ligand Pharmaceuticals' current Days Inventory of 285.35 is 28% above median its 10-year median of 223.03. Over the past 10 years, this metric has ranged from a low of 116.49 to a high of 646.93. The Biotechnology industry median Days Inventory is 183.88. Ligand Pharmaceuticals' value of 285.35 is 55.2% above this industry median. Based on the distribution chart, Ligand Pharmaceuticals ranks #440 out of 638 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ligand Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ligand Pharmaceuticals' Days Inventory compare to DFTX and CGON?
According to the Biotechnology industry distribution chart, Ligand Pharmaceuticals ranks #440 out of 638 companies for Days Inventory. This places Ligand Pharmaceuticals in the lower half of its industry. The industry median Days Inventory is 183.88. Ligand Pharmaceuticals' value of 285.35 is 55.2% above this benchmark. Historically, Ligand Pharmaceuticals' own Days Inventory has ranged from 116.49 to 646.93 over the past decade. While the company's 10-year median is 223.03 vs. the industry median of 183.88, Ligand Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.88, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ligand Pharmaceuticals's current Days Inventory of 285.35 is 55.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Ligand Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Inventory is 183.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ligand Pharmaceuticals's current Days Inventory is 285.35, which is 28% above median its own 10-year median of 223.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ligand Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ligand Pharmaceuticals (FRA:LGDN) is currently considered Significantly Overvalued. The stock's GF Value™ is €150.40, compared to a current price of €266.00 — trading 76.9% above its estimated fair value. The current Days Inventory is 285.35, which is 28% above median its 10-year median of 223.03 and 55.2% above the Biotechnology industry median of 183.88. Ligand Pharmaceuticals' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Ligand Pharmaceuticals (FRA:LGDN), the current Days Inventory is 285.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ligand Pharmaceuticals (FRA:LGDN) Overvalued in 2026?
Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued.
The current stock price of €266.00 is trading 76.9% above its estimated GF Value™ of €150.40.
GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:LGDN:
Days Inventory: 285.35 (28% above median its 10-year median of 223.03)
GF Value™: €150.40 vs. price of €266.00 (76.9% above fair value)
Industry Position: 55.2% above the Biotechnology median (#440 of 638)
No single metric tells the full story. See the FRA:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
73GF Score
Get the complete analysis for FRA:LGDN
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LGDN has been successfully added to your 
